Acorn Capital Advisors LLC Acquires 472,315 Shares of Protara Therapeutics, Inc. $TARA

Acorn Capital Advisors LLC increased its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) by 36.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,752,115 shares of the company’s stock after buying an additional 472,315 shares during the quarter. Protara Therapeutics comprises approximately 3.5% of Acorn Capital Advisors LLC’s investment portfolio, making the stock its 11th biggest position. Acorn Capital Advisors LLC owned about 4.54% of Protara Therapeutics worth $5,309,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in TARA. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Protara Therapeutics during the 2nd quarter valued at $30,000. Quadrature Capital Ltd bought a new stake in Protara Therapeutics during the second quarter worth about $35,000. Charles Schwab Investment Management Inc. acquired a new stake in Protara Therapeutics during the first quarter worth about $64,000. JPMorgan Chase & Co. bought a new position in Protara Therapeutics in the second quarter valued at approximately $46,000. Finally, Los Angeles Capital Management LLC bought a new stake in Protara Therapeutics during the second quarter worth $47,000. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Stock Down 5.2%

Shares of TARA stock opened at $5.70 on Friday. Protara Therapeutics, Inc. has a twelve month low of $2.77 and a twelve month high of $7.82. The stock’s fifty day simple moving average is $5.70 and its 200 day simple moving average is $4.10. The firm has a market capitalization of $219.95 million, a P/E ratio of -3.99 and a beta of 1.38.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.08. As a group, equities research analysts expect that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.